Regenerative medicine, in conjunction with personalized medicine, is responsible for the next major paradigm shift in modern medicine. However, neither regenerative nor personalized precision medicine are subjects traditionally found in the curriculum of U.S. medical schools. As such, this emergence has been met with skepticism, doubt and confusion.
One area where COVID-19 has had a substantial impact is the development and manufacturing of medicines, medical devices, and pharmaceutical products. The CDMO industry is showing enormous growth and is projected to become a $315 billion industry by 2026. However, the demand for products skyrocketed so quickly that supply has not been able to keep pace. According to Dr. Ian White, president and CSO of Neobiosis, a UF Innovate | Sid Martin Biotech resident company that focuses on the science of regenerative medicine, demand has caused a two-year backlog of desperately needed cellular and acellular products for use in research and clinical trials directed at treating the COVID-19 virus and its complications (AKA Post-COVID Syndrome).
Dr. Ian White, founder, president and chief scientific officer of UF Innovate | Sid Martin Biotech resident Neobiosis, a CDMO developing new drug applications with the FDA, producing therapeutic regenerative medicine products for human use, is featured on The Huxley Morton Podcast.
Dr. Ian White, founder, president and CSO of UF Innovate | Sid Martin Biotech resident Neobiosis is featured on the Health Hacks podcast.
UF Innovate | Sid Martin Biotech resident Neobiosis, a clinical-stage contract development and manufacturing organization, managed by scientists and physicians and focused on the science of regenerative medicine, announced the appointment of Pascal Goldschmidt, M.D. as Chief Medical Officer.
Cardiovascular disease kills more than 650,000 Americans annually. Those who survive myocardial infarction remain at risk of death because the human heart has a very limited ability to repair itself. No one has yet found a method that leads to cardiovascular regeneration for a damaged human heart. But all that may change thanks to a revolutionary medical paper written by Dr. Ian White, president and CSO of UF Innovate | Sid Martin Biotech resident Neobiosis, a company that focuses on the science of regenerative medicine.
In this article, UF Innovate | Sid Martin Biotech resident client Neobiosis founder Ian White explains how his company is using regenerative medicine to develop products to treat coronavirus long hauler syndrome. (Note: the University of Florida Innovate Center mentioned in the story should be UF Innovate | Sid Martin Biotech.)